GC
IPOs - All articles
-
Korea’s Big Hit files for IPO review
South Korean firm Big Hit Entertainment, manager of popular K-pop boy band BTS, has applied for a preliminary review of its IPO with the Korea Exchange.
-
More Chinese IPOs expected for London as US tensions grow
Chinese companies are likely to consider London as an alternative foreign listing venue, according to sources speaking to GlobalCapital, following a regulatory crackdown in New York and increased political tensions between the US and China.
-
Yeahka wins top end pricing for HK$1.6bn IPO
Chinese online payments platform Yeahka rode on strong demand from both institutional and retail investors for its Hong Kong IPO, to price the HK$1.64bn ($211.9m) deal at the top of guidance.
-
Chinese cancer detection firm Burning Rock eyes US IPO
Burning Rock Biotech is planning to float on Nasdaq for as much as $100m.
-
JD.com, NetEase ready $5bn secondary IPOs in HK
Chinese internet giants JD.com and NetEase are targeting mid-June to launch their respective Hong Kong listings, according to sources familiar with the matter.
-
SK Biopharma preps Korea’s debut 2020 IPO, eyes $780m
SK Biopharmaceuticals is set to reopen the South Korean IPO market with a W959.3bn ($779.9m) listing, according to a source close to the deal.
-
Yeahka kicks off $212m Hong Kong IPO
Yeahka, a Chinese online payments platform, has launched its Hong Kong listing of up to HK$1.6bn ($212m).
-
Nasdaq pushes for Luckin Coffee delisting
Nasdaq's board is planning to delist Luckin Coffee’s shares, after the Chinese company revealed fabricated accounts in April.
-
Kintor Pharma prices IPO high to net $240m
Kintor Pharmaceutical has notched another success for the healthcare sector, raising HK$1.86bn ($240m) from its IPO after pricing the deal at the top of the marketed range.
-
Trump threatens US-listed Chinese firms
Chinese stocks are in Donald Trump’s firing line again, after the US president announced he is “looking very strongly” at any companies not following local accounting guidelines.
-
Dada Nexus, Legend Bio ready Nasdaq IPOs
Dada Nexus, an operator of Chinese on-demand retail and delivery platforms, and Legend Biotech Corp both set the ball rolling for Nasdaq IPOs this week.
-
Genscript Biotech to spin off unit in $100m Nasdaq IPO
Genscript Biotech Corp is planning to spin-off and list subsidiary Legend Biotech Corp in a potential $100m Nasdaq IPO. The firm submitted listing documents to the US regulator on Wednesday.
-
JD-backed Dada Nexus files for $100m US listing
Dada Nexus, an operator of Chinese on-demand retail and delivery platforms, has set the ball rolling for a Nasdaq IPO.
-
Tencent-backed Yeahka readies Hong Kong IPO
Online payments platform Yeahka has begun stirring up investor interest in its Hong Kong IPO, which is set to be launched next week, according to a source close to the deal.
-
Kintor Pharma sets Hong Kong IPO in motion
China-based Kintor Pharmaceutical has kicked off bookbuilding for its Hong Kong listing, the latest in a stream of healthcare IPOs in the city. The issuer is targeting HK$1.86bn ($240.1m) in proceeds.
-
Peijia Medical pockets HK$2.34bn from hot IPO
Peijia Medical bagged HK$2.34bn ($302m) from its IPO after winning huge support from institutional and retail investors, according to a source close to the deal.
-
Kingsoft Cloud bumps up US IPO to $510m
Chinese company Kingsoft Cloud Holdings has raised $510m after boosting the size of its Nasdaq float.
-
Kingsoft Cloud runs rapid roadshow for $450m US IPO
Kingsoft Cloud Holdings is on the road with its up to $450m Nasdaq IPO. Thanks to strong pre-launch demand, it is running a quick three-day bookbuild, according to a source close to the deal.
-
Peijia Medical to close HK$2.3bn IPO early
Peijia Medical is set to close bookbuilding for its HK$2.34bn ($302m) listing early after institutional investor orders flooded the deal.
-
Kingsoft Cloud sets $450m target for US IPO
Kingsoft Cloud Holdings is looking to raise $450m from its Nasdaq IPO, finalising the listing terms on Monday.
-
Peijia Medical launches $302m Hong Kong IPO
Mainland-based Peijia Medical is set to be the third healthcare company to list in Hong Kong since the coronavirus outbreak in late January, opening books on Tuesday for a HK$2.34bn ($302m) IPO.
-
Central China New Life kicks off $279m HK listing
Central China New Life, a property management company, has launched marketing for its Hong Kong IPO as it aims to raise up to HK$2.16bn ($278.6m). The Mainland-based firm has begun virtual meetings with investors as the threat of Covid-19 continues to prevent any hopes of physical meetings.
